Sana Biotechnology, Inc. (SANA) — SEC Filings

Latest SEC filings for Sana Biotechnology, Inc. (SANA), explained in plain English.

Sentiment Overview: 37 neutral, 1 mixed

Recent Filings (38)

• Sana Biotechnology Files Form 4 on Ownership Changes — 4 · 2026-04-08T16:16:24-04:00 [neutral] Risk: low
  On April 8, 2026, Sana Biotechnology, Inc. filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions that occurred
• Sana Biotech Narrows Q3 Loss Amid R&D Cuts, Raises $109M Capital — 10-Q · 2025-11-06T00:00:00.000Z [mixed] Risk: high
  Sana Biotechnology, Inc. reported a net loss of $42.15 million for the three months ended September 30, 2025, a significant improvement from the $59.92 million
• Sana Biotechnology Announces Board and Executive Changes — 8-K · 2025-09-05T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. announced on September 4, 2025, a change in its board of directors and executive compensation arrangements. The filing details the depa
• Sana Biotechnology Announces Board and Executive Compensation Changes — 8-K · 2025-08-29T00:00:00.000Z [neutral] Risk: medium
  On August 28, 2025, Sana Biotechnology, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
• Sana Biotechnology Files 8-K on Financials — 8-K · 2025-08-11T00:00:00.000Z [neutral] Risk: low
  Sana Biotechnology, Inc. filed an 8-K on August 11, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Sana Biotechnology Files 8-K for Material Agreement — 8-K · 2025-08-07T00:00:00.000Z [neutral] Risk: medium
  On August 6, 2025, Sana Biotechnology, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial s
• Sana Biotechnology Files 8-K on Operations and Other Events — 8-K · 2025-08-06T00:00:00.000Z [neutral] Risk: medium
  On August 6, 2025, Sana Biotechnology, Inc. filed an 8-K report. The filing indicates the company is providing information regarding its results of operations a
• Sana Biotechnology Files 8-K with Financials — 8-K · 2025-06-23T00:00:00.000Z [neutral] Risk: low
  On June 23, 2025, Sana Biotechnology, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate ac
• Sana Biotechnology Reports on Security Holder Vote — 8-K · 2025-06-06T00:00:00.000Z [neutral] Risk: low
  Sana Biotechnology, Inc. filed an 8-K on June 6, 2025, reporting on a matter submitted to a vote of its security holders on June 5, 2025. The filing does not pr
• Sana Biotechnology Files Q1 2025 10-Q — 10-Q · 2025-05-08T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations, including refere
• Sana Biotechnology Files Definitive Proxy Statement — DEF 14A · 2025-04-25T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. filed its definitive proxy statement (DEF 14A) on April 25, 2025, for its annual meeting of stockholders scheduled for June 5, 2025. Th
• 10-K Filing — 10-K · 2025-03-17T00:00:00.000Z [neutral]
• Sana Biotechnology Files 8-K — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  On January 13, 2025, Sana Biotechnology, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits, wi
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• Sana Biotechnology Files Q3 2024 10-Q — 10-Q · 2024-11-08T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its operati
• SC 13G/A Filing — SC 13G/A · 2024-11-04T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-10-22T00:00:00.000Z [neutral]
• Sana Biotechnology Appoints New CEO — 8-K · 2024-10-08T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. announced on October 4, 2024, the appointment of Dr. Jay L. D. Bradner as its new Chief Executive Officer, effective immediately. Dr. B
• Sana Biotechnology Announces Board and Executive Changes — 8-K · 2024-09-12T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. announced on September 6, 2024, changes related to its board of directors and executive compensation. Specifically, the company reporte
• Sana Biotechnology Files Q2 2024 10-Q — 10-Q · 2024-08-08T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position, including assets and liabilities, a
• Sana Biotechnology Reports on Shareholder Vote Matters — 8-K · 2024-06-07T00:00:00.000Z [neutral] Risk: low
  Sana Biotechnology, Inc. filed an 8-K on June 7, 2024, reporting on matters submitted to a vote of security holders as of June 6, 2024. The filing does not cont
• Sana Biotechnology, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-08T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. (SANA) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Sana Biotechnology, Inc. filed a 10-Q report for the quarter ended
• Sana Biotechnology, Inc. Announces 2024 Annual Meeting of Stockholders on June 6 — DEF 14A · 2024-04-26T00:00:00.000Z [neutral] Risk: low
  Sana Biotechnology, Inc. (SANA) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 Annual Meeting of Stockholders for Sana Biotechnology
• Sana Biotechnology Appoints New CMO, Adds Directors — 8-K · 2024-04-18T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. announced on April 18, 2024, the appointment of Dr. Jay L. D. Ian as Chief Medical Officer and the election of Dr. Ian and Ms. Sarah E.
• SC 13G/A Filing — SC 13G/A · 2024-04-03T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-03-07T00:00:00.000Z [neutral]
• Sana Biotechnology, Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-29T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. (SANA) filed a Annual Report (10-K) with the SEC on February 29, 2024. Sana Biotechnology, Inc. filed its annual report on Form 10-K fo
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• ARCH Venture Funds Update Sana Bio Stake on Dec 31, 2023 — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  ARCH Venture Fund IX, L.P. and its associated entities, including ARCH Venture Fund X, L.P., filed an amended Schedule 13G/A on February 9, 2024, for their hold
• FMR LLC & Abigail Johnson Hold 7.99% Stake in Sana Bio — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  FMR LLC, a major investment firm, and its Chairman and CEO, Abigail P. Johnson, have updated their ownership stake in Sana Biotechnology, Inc. As of February 9,
• Sana Bio Files 8-K on Material Agreement; Details Undisclosed — 8-K · 2024-02-08T00:00:00.000Z [neutral] Risk: medium
  Sana Biotechnology, Inc. filed an 8-K on February 8, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on Februar
• Sana Biotechnology Files 8-K on Operations & Financial Condition — 8-K · 2024-02-07T00:00:00.000Z [neutral]
  Sana Biotechnology, Inc. filed an 8-K on February 7, 2024, to report on its results of operations and financial condition, along with other events. This filing,
• Baillie Gifford Amends Sana Bio Stake; Passive Investment Noted — SC 13G/A · 2024-01-26T00:00:00.000Z [neutral]
  Baillie Gifford & Co, a prominent investment management firm, filed an amended SC 13G/A on January 26, 2024, indicating a change in their ownership of Sana Biot
• SANA Files 8-K for Regulation FD Disclosure & Exhibits — 8-K · 2024-01-09T00:00:00.000Z [neutral]
  Sana Biotechnology, Inc. filed an 8-K on January 9, 2024, to disclose information under Regulation FD and to file financial statements and exhibits. This filing